Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti CTLA-4 Monoclonal Antibody (Checkmate 168: CHECKpoint Pathway for nivoluMAb Clinical Trial Evaluation 168)
Principal Investigator
Sasha SmiljanicOverview
Body Locations and Systems
MelanomaDisorders and Conditions
MelanomaClinicalTrials.gov#
NCT02142218Status
Closed for RecruitmentStudy Start/End
Jan 1, 2015 to Sep 2, 2019Locations
Lions Gate HospitalName/Title
Vall Sahraei, Clinical Trials Nurse CoordinatorPhone
604-988-3131 ext. 4934Purpose of Study
The primary purpose of this study is to provide treatment with Nivolumab to subjects with histologically confirmed stage III (unresectable) or stage IV advanced melanoma who have progressed on or after prior treatment with an anti-CTLA4-containing therapy and for subjects with known BRAF mutation, also progressed on or after treatment with a BRAF inhibitor.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.